OncoSec - IMMUNOPULSE® IL-12
Manufactured by OncoSec
To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a...
To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body.
OncoSec is currently investigating ImmunoPulse® IL-12 for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate ImmunoPulse® IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.
OncoSec is currently investigating ImmunoPulse® IL-12 for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate ImmunoPulse® IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.
Active Questions & AnswersAsk a Question
There are no current Discussions
DNA Sequencing Reagents Service ProvidersView All (3)
Documents & Manuals
There are no Documents or Manuals available.
Features
There are no Features available.
General Specifications
There are no General Specifications available.